New study explores ivosidenib dosing for cancer patients with organ issues
NCT ID NCT07006688
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study is testing the safety and how the body handles ivosidenib in 30 adults with IDH1-mutated cancers who also have liver or kidney problems. Participants take a daily ivosidenib pill and are monitored closely with blood tests and check-ups. The goal is to learn how organ impairment affects the drug, not to treat the cancer directly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ivosidenib (oral tablet)
What this could lead to
If successful, this could help doctors understand how to safely dose ivosidenib in patients with liver or kidney problems, potentially expanding treatment access.
What could go wrong
This is a very early, small Phase 1 study with only 30 participants. It focuses on safety and drug levels, not on curing cancer. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDH1-MUTATED MALIGNANCIES are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
RECRUITINGSeoul, 5505, South Korea
-
Emory University
RECRUITINGAtlanta, Georgia, 30322, United States
-
Fakultni nemocnice Ostrava
RECRUITINGOstrava, 70800, Czechia
-
Fakultni nemocnice v Motole FN Motol
RECRUITINGPrague, HlavnÃ- Mesto Praha, 15000, Czechia
-
Hospital Universitari Vall d'Hebron
NOT_YET_RECRUITINGBarcelona, 8035, Spain
-
Hospital Universitario 12 de Octubre
RECRUITINGMadrid, 28050, Spain
-
Hospital de Base de Sao Jose do Rio Preto
RECRUITINGSão José do Rio Preto, São Paulo, 15090-000, Brazil
-
Icon Cancer Centre
RECRUITINGSouth Brisbane, Queensland, 4101, Australia
-
Instituto do Cancer do Estado de Sao Paulo
RECRUITINGSão Paulo, 01246-000, Brazil
-
MD Anderson
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
-
Royal Adelaide Hospital
RECRUITINGAdelaide, South Australia, 5000, Australia
-
START - Hospital HM Nou Delfos
RECRUITINGBarcelona, 8023, Spain
-
START Madrid - Fundacion Jimenez Diaz
RECRUITINGMadrid, 28040, Spain
-
START Madrid Centro Oncologico Clara Campal Sanchinarro Univesrity Hospital
RECRUITINGMadrid, 28050, Spain
-
Seoul National University Bundang Hospital
RECRUITINGSeongnam-si, Gyeonggi-do, 13620, South Korea
-
Seoul National University Hospital
RECRUITINGSeoul, 3080, South Korea
-
Severence Hospital, Yonsei University Health Systems
RECRUITINGSeoul, 3722, South Korea
-
University Hospital Brno
WITHDRAWNBrno, 62500, Czechia
-
Vseobecna fakultni nemocnice v Praze
NOT_YET_RECRUITINGPrague, 128 00, Czechia